BRCA1 and neoplasm: Costs for patients treated with olaparib, enzalutamide, or abiraterone increased substantially in the subgroup of patients with a tumor harboring at least one of three prespecified gene alterations (BRCA1, BRCA2, or ATM) versus those with at least one of 15 prespecified gene alterations (Table 5).